Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Breast Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Breast Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Breast Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Ovarian Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Ovarian Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Prostate Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Prostate Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Prostate Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Colorectal Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Colorectal Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Melanoma: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Melanoma

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Pancreatic Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Gastric Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Gastric Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Non-Small Cell Lung Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Esophageal Cancer: Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Esophageal Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Esophageal Cancer

Data Insights

Salutaxel by Shenzhen Salubris Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Salutaxel is under clinical development by Shenzhen Salubris Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell...

Likelihood of Approval and Phase Transition Success Rate Model - Salutaxel in Head And Neck Squamous Cell Carcinoma (HNSC)